Literature DB >> 23701167

Diagnosis of thyroid cancer: state of art.

Myriem Boufraqech1, Dhaval Patel, Yin Xiong, Electron Kebebew.   

Abstract

INTRODUCTION: Thyroid cancer is the most common endocrine cancer in the USA and its incidence is increasing worldwide. Thyroid fine-needle aspiration biopsy (FNA) and cytologic analysis is the most cost-effective approach to distinguish between malignant and benign thyroid nodules. However, up to 30% of thyroid FNA biopsy results are inconclusive. AREAS COVERED: In this article, the authors provide an update on the current status and emerging approaches for improving thyroid cancer diagnosis. This review covers imaging, genetic and genomic approaches being used or in development to help distinguish between malignant and benign thyroid nodules. EXPERT OPINION: There has been considerable progress in improving thyroid cancer diagnosis. The molecular markers analysis to avoid diagnostic surgeries seems to be promising. However, the clinical utility and accuracy of some markers reported in this review are not conclusive and need to be validated as clinical diagnostic tool.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23701167     DOI: 10.1517/17530059.2013.800481

Source DB:  PubMed          Journal:  Expert Opin Med Diagn        ISSN: 1753-0059


  8 in total

1.  Methylation markers differentiate thyroid cancer from benign nodules.

Authors:  J K Stephen; K M Chen; J Merritt; D Chitale; G Divine; M J Worsham
Journal:  J Endocrinol Invest       Date:  2017-06-13       Impact factor: 4.256

2.  (99m)Tc-labeled-rhTSH analogue (TR1401) for imaging poorly differentiated metastatic thyroid cancer.

Authors:  Filippo Galli; Isabella Manni; Giulia Piaggio; Lajos Balogh; Bruce D Weintraub; Mariusz W Szkudlinski; Valerie Fremont; Rudi A J O Dierckx; Alberto Signore
Journal:  Thyroid       Date:  2014-06-20       Impact factor: 6.568

3.  Methylation Markers for Early Detection and Differentiation of Follicular Thyroid Cancer Subtypes.

Authors:  Josena K Stephen; Kang Mei Chen; Jason Merritt; Dhananjay Chitale; George Divine; Maria J Worsham
Journal:  Cancer Clin Oncol       Date:  2015-06-15

4.  A population-based study of the three major variants of papillary thyroid carcinoma.

Authors:  Junming Xu; Yingying Zhang; Jun Liu; Shenglong Qiu; Min Wang
Journal:  J Int Med Res       Date:  2021-02       Impact factor: 1.671

5.  Silencing of LIM and SH3 Protein 1 (LASP-1) Inhibits Thyroid Cancer Cell Proliferation and Invasion.

Authors:  Wei Gao; Jiakai Han
Journal:  Oncol Res       Date:  2016-11-17       Impact factor: 5.574

6.  Histopathological prognosis of papillary thyroid carcinoma associated with nutritional status of vitamins A and E.

Authors:  Lara Lima-Antoine; Julianna Lys de Sousa Alves Neri; Thaisa Cristina Tavares de Melo; Isabela Samária Fernandes Leite; Diego Marques da Costa Santos; Jéssica Nayara Góes de Araújo; Ana Gabriella da Costa Lemos Silva; Nathália Kelly de Araújo; Carlos C de Oliveira Ramos; Sheila Ramos de Miranda Henriques Tarrapp; Andre Ducati Luchessi; Clélia de Oliveira Lyra; Karla Danielly da Silva Ribeiro; Vivian Nogueira Silbiger
Journal:  Eur J Clin Nutr       Date:  2021-07-06       Impact factor: 4.016

7.  Zinc finger E-box-binding homeobox 1: its clinical significance and functional role in human thyroid cancer.

Authors:  Yan Zhang; Gang Liu; Shihe Wu; Futing Jiang; Jiangping Xie; Yuhong Wang
Journal:  Onco Targets Ther       Date:  2016-03-29       Impact factor: 4.147

8.  A new computational model for human thyroid cancer enhances the preoperative diagnostic efficacy.

Authors:  Tuo Li; Jianguo Sheng; Weiqin Li; Xin Zhang; Hongyu Yu; Xueyun Chen; Jianquan Zhang; Quancai Cai; Yongquan Shi; Zhimin Liu
Journal:  Oncotarget       Date:  2015-09-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.